Characterizing Treatment Non-responders vs. Responders in Completed Alzheimer's Disease Clinical Trials.

ABSTRACT: Alzheimer's disease (AD) patients have varying responses to AD drugs and there may be no single treatment for all AD patients. Trial after trial shows that identifying non-responsive and responsive subgroups and their corresponding moderators will provide better insights into subject selection and interpretation in future clinical trials. We aim to extensively investigate pre-treatment features that moderate treatment effect of Galantamine, Bapineuzumab, and Semagacestat from completed trial data. We obtained individual-level patient data from ten randomized clinical trials. Six Galantamine trials and two Bapineuzumab trials were from Yale University Open Data Access Project and two Semagacestat trials were from the Center for Global Clinical Research Data. We included a total of 10,948 su

SUBMITTER: Wang D 

PROVIDER: S-EPMC10635230 | biostudies-literature | 2023 Oct

REPOSITORIES: biostudies-literature